At present, the progress of oral antiviral drugs for hepatitis C can be described as fast-changing and evangelical, and various generic products are also available in India, Bangladesh, Laos and other places one after another. The cost of traditional interferon therapy in China is about 70,000-80,000 RMB. In September 2014, Gilead reached an agreement with seven generic companies in India to license a generic version of Sovaldi manufactured by Gilead. These companies have the autonomy to determine the selling price of the generic drug, although they are required to pay Gilead a commission based on sales. According to publicly available information, the agreement between Gilead and the seven generic companies in India provides for the sale of these generics to 91 developing countries. However, China is not among the 91 countries and regions specified in the agreement between the two parties. This means that even if Gilead is allowed to enter China in the future, the price of its hepatitis C drug could be about 90 times higher than the price in India. In Gilead’s view, China is no longer a developing country, Gregg Alton, executive vice president of Gilead, said in a statement, “Sovaldi sells for $300 a bottle (28 tablets) in India, which is the company’s pricing for low-income countries and is similar to the price negotiated by the Egyptian government. We expect that local production of the drug with our partners in India, higher volumes and continued R&D will bring Sovaldi’s selling price down further at a later stage.” Gilead has different pricing strategies for different countries. Michel, Gilead’s director of global public relations, told The Economic Observer, “The final price will depend on each country’s treatment needs, healthcare infrastructure, and the government’s commitment and determination to expand effective therapies for hepatitis C virus.” Indian drug companies are able to obtain the right to make generic versions because India has been implementing a “compulsory drug licensing system,” under which the government grants licenses to other companies to use a patent without the consent of the patentee in special circumstances. Generally speaking, once an expensive drug is marketed in Western countries, Indian pharmaceutical companies can copy the same product under the protection of their own patent laws. In the 1970s, the Indian government did not recognize patents on drugs from Western countries at all. It was only in 2005, as part of an agreement with the World Trade Organization, that India began to restore patent protection for pharmaceuticals. in 2003, the WTO General Council adopted the Implementing Resolution of Paragraph 6 of the Doha Declaration, which clarified that developing and least developed member countries could, in the event of public health crises, such as AIDS, malaria, tuberculosis and other epidemic diseases, without the consent of the patentee Implement a compulsory licensing system to produce, sell and use patented products. A market analyst said that for Gilead, instead of letting Indian generic drugs take over the market, it would be better to selectively “license” the drugs and at least get a percentage of the sales. However, in China, the Patent Law stipulates that Chinese pharmaceutical companies are not allowed to produce “generic drugs” during the patent protection period of the drug. Although the Chinese government may grant some Chinese pharmaceutical companies the right to use the patented technology of foreign manufacturers to produce generic drugs during the patent protection period for the purpose of protecting “public health” under the “patent compulsory license” system similar to that of India, the Patent Law has been enacted for 30 years. However, in the 30 years since the enactment of the Patent Law, China has not implemented a single case of “patent compulsory licensing”. On September 16, 2012, the United Nations released the “Annual Report on MDG Gap Workers”, which concluded that the development of generic drug industry is an important guarantee for the third world countries to improve the health level and people’s health status, and appreciated and affirmed the efforts of India and other countries to strengthen the production of low-cost generic drugs. However, in China, as long as they fail to obtain the approval of the State Drug Administration, the drugs openly sold in the domestic market are illegal. Where do we go from here, Chinese hepatitis C patients, magical hepatitis C drugs, cheap generics, and strict legal provisions?!